The main focus of the research group is in translational research in gynaecological cancers. In particular biomarker discovery and development (specifically immunological markers) in ovarian and endometrial cancers. The biomarkers are now in the process of being tested for diagnosis and surgical prognosis. The concept of predicting surgical outcome in ovarian cancer is a step in developing personalised medicine and providing patients with best care possible.
Recent advances in oncolgy have improved survival in patients with cancer but research into surgery may have additional benefits for the patient. Clinical research into optimal treatment of cervival preinvasive lesions has been a focus. We have shown that clear margins of resection has a significant effect on reducing risk of recurrence from preinvasive disease.
et al., 2017, Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer, Clinical Cancer Research, Vol:23, ISSN:1078-0432, Pages:3453-3460
et al., 2017, NY-ESO-1 expression in DCIS: A new predictor of good prognosis., Oncoscience, Vol:4, ISSN:2331-4737, Pages:33-40
Flower KJ, Ghaem-Maghami S, Brown R, 2017, Is there a role for epigenetic enhancement of immunomodulatory approaches to cancer treatment?, Curr Cancer Drug Targets
et al., 2017, Ultrasound-Guided Laparoscopic Ovarian Wedge Resection in Recurrent Serous Borderline Ovarian Tumours., Int J Gynecol Cancer
et al., 2017, Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test, Cochrane Database of Systematic Reviews, ISSN:1469-493X